Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
Holding CGON?
Track your performance easily
CGON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.77 - $50.23
Previous Close$28.67
Volume1.47M
Average Volume (3M)605.77K
Market Cap
$2.13B
Enterprise Value$1.59B
Total Cash (Recent Filing)$540.71M
Total Debt (Recent Filing)$296.00K
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 12, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding67,629,675
10 Day Avg. Volume1,276,324
30 Day Avg. Volume605,773
Standard Deviation0.11
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.61
Price to Sales (P/S)2770.44
Price to Cash Flow (P/CF)-29.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.33K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-28.34
Forecast
1Y Price Target
$67.83Price Target Upside136.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
CG Oncology, Inc. News
PremiumCompany Announcements
CG Oncology Reports Promising Phase 3 Trial ResultsPremiumCompany Announcements
CG Oncology’s Financial Results and Clinical DevelopmentsBulls Say, Bears Say
Bulls Say
Financial StabilityCG Oncology's strong cash position of $540.7 million is projected to fund operations through 2027, providing a solid financial foundation to support the company's growth and potential market expansion.
Market PotentialThe durability and safety of cretostimogene position it as a transformative therapy in the competitive landscape of bladder cancer treatments, with broad efficacy observed across diverse patient populations.
Treatment Efficacy And SafetyCretostimogene demonstrates compelling efficacy with a sustained complete response rate of 75% in patients with BCG-unresponsive non-muscle invasive bladder cancer, while maintaining a strong safety profile with zero Grade 3+ treatment-related adverse events.
Bears Say
Clinical TrialsThe SunRISe-2 study was discontinued due to TAR-200 failing to show superiority to the chemoradiation comparator arm.
Market CompetitionThe commercial bar is high for CG Oncology given the competition is BCG, indicating challenges in gaining market share.
Stock PressureThere are limited stock-moving catalysts between the Society of Urologic Oncology meeting and potential approval of cretostimogene, which could result in some pressure on shares even with positive results.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $25.77 and its highest was $50.23 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
Currently, no data Available
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Nov 12, 2024 which is 40 days ago.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 08, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.356 by $0.076.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -$0.35.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 76,129,680 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.356. Following the earnings report the stock price went down -6.828%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Among the largest hedge funds holding CG Oncology, Inc.’s share is RA Capital Management. It holds CG Oncology, Inc.’s shares valued at 53M.
---
CG Oncology, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.83 (136.59% Upside)
$67.83 (136.59% Upside)
Blogger Sentiment
Neutral
CGON Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 590.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.
---
CGON Stock 12 Month Forecast
Average Price Target
$67.83
▲(136.59% Upside)
Technical Analysis
Best Analysts Covering CGON
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-22.35%
reiterated a buy rating 17 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -22.35% per trade.
---